CBPO:NSD-China Biologic Products Holdings, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 119.99

Change

0.00 (0.00)%

Market Cap

USD 4.63B

Volume

0.39M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-1.40 (-0.83%)

USD66.76B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-3.78 (-1.72%)

USD56.88B 21.36 15.53
REGN Regeneron Pharmaceuticals, Inc

-16.05 (-3.17%)

USD54.26B 16.60 12.83
BNTX BioNTech SE

+7.15 (+4.42%)

USD37.72B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

-0.79 (-0.47%)

USD37.13B 61.79 35.79
BGNE BeiGene, Ltd

+9.06 (+3.00%)

USD28.73B N/A N/A
SGEN Seagen Inc

-3.84 (-2.60%)

USD26.74B 43.77 35.78
RPRX Royalty Pharma plc

+0.43 (+1.01%)

USD25.97B 22.60 15.19
GMAB Genmab A/S

+0.28 (+0.77%)

USD23.74B 26.59 3.37
CVAC CureVac N.V

+1.16 (+1.03%)

USD20.99B N/A N/A

ETFs Containing CBPO

Symbol Name Weight Mer Price(Change) Market Cap
EELV Invesco S&P Emerging Mark.. 0.00 % 0.30 %

-0.21 (-0.85%)

USD0.28B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.59% 53% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.59% 53% F 38% F
Trailing 12 Months  
Capital Gain 11.95% 43% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.95% 43% F 20% F
Trailing 5 Years  
Capital Gain -6.80% 52% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.80% 52% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 2.29% 37% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.29% 36% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 23.36% 94% A 68% D+
Risk Adjusted Return 9.82% 40% F 33% F
Market Capitalization 4.63B 92% A- 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.41 26% F 35% F
Price/Book Ratio 2.31 78% C+ 60% D-
Price / Cash Flow Ratio 17.91 6% F 25% F
EV/EBITDA 14.01 31% F 59% F
Management Effectiveness  
Return on Equity 9.25% 95% A 74% C
Return on Invested Capital 8.68% 90% A- 78% C+
Return on Assets 5.82% 96% A 87% B+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 7.23 22% F 10% F
Short Percent 3.45% 74% C 50% F
Beta 0.42 87% B+ 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector